Dr. Schulz received her Ph.D. from the University of North Carolina, where her work focused on investigating the cellular mechanism of a novel immune-agonizing microparticle delivery platform for cancer therapy. Prior to joining Nuventra, Dr. Schulz was a regulatory affairs intern at Cato Research, where she worked on clinical trial deliverables for a wide range of disease interests.
Education